Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $4.80

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have earned an average rating of "Moderate Buy" from the five brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $4.80.

A number of research analysts have weighed in on the stock. StockNews.com raised shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. Royal Bank of Canada reiterated an "outperform" rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Finally, Robert W. Baird cut their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 7th.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI traded up $0.05 during trading on Friday, reaching $0.83. 546,296 shares of the stock were exchanged, compared to its average volume of 1,425,958. Karyopharm Therapeutics has a 1-year low of $0.62 and a 1-year high of $1.95. The stock has a fifty day moving average of $0.90 and a two-hundred day moving average of $1.12. The firm has a market cap of $103.87 million, a price-to-earnings ratio of -0.64 and a beta of 0.21.

Insider Activity at Karyopharm Therapeutics

In related news, Director Deepika Pakianathan sold 360,744 shares of the company's stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $1.00, for a total value of $360,744.00. Following the transaction, the director now owns 11,209 shares in the company, valued at $11,209. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders sold 1,279,081 shares of company stock valued at $1,237,898. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several institutional investors have recently added to or reduced their stakes in KPTI. Los Angeles Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth about $339,000. BNP Paribas Financial Markets grew its position in shares of Karyopharm Therapeutics by 6.5% during the 4th quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company's stock valued at $1,530,000 after purchasing an additional 108,286 shares in the last quarter. Panagora Asset Management Inc. bought a new position in shares of Karyopharm Therapeutics in the fourth quarter worth $197,000. Monashee Investment Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth $115,000. Finally, Simplicity Wealth LLC purchased a new position in Karyopharm Therapeutics during the first quarter worth about $66,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).